[vc_row][vc_column width="1/1"][vc_single_image image="19" alignment="center" border_color="grey" img_link_target="_self"][/vc_column][/vc_row][vc_row][vc_column width="1/1"][vc_single_image image="27" alignment="center" border_color="grey" img_link_target="_self"][/vc_column][/vc_row][vc_row][vc_column width="1/1"][vc_single_image image="24" alignment="center" border_color="grey" img_link_target="_self"][/vc_column][/vc_row][vc_row][vc_column width="1/1"][vc_single_image image="26" alignment="center" border_color="grey" img_link_target="_self"][/vc_column][/vc_row][vc_row][vc_column width="1/1"][vc_single_image image="25" alignment="center" border_color="grey" img_link_target="_self"][/vc_column][/vc_row][vc_row][vc_column width="1/1"][vc_column_text]

Przypisy

1. Glikol polietylenowy PEG 400 0,25%.
2. Aragona P. Long term treatment with sodium hyaluronate containing artificial tears reduces ocular surface damage in patients with dry eye.
3. Abelson MB, Anderson R. Demystifying Demulcents. Review of Ophthalmology. Published 15 November 2006.

blink^®, blink contacts^®, blink^® intensive i blink^® intensive PLUS są znakami towarowymi firmy Abbott Medical Optics Inc., jej spółek zależnychoraz podmiotów stowarzyszonych. Johnson & Johnson Poland Sp. z o.o., ul. Iłżecka 24, 02-135 Warszawa, Spółka zarejestrowanaw Sądzie Rejonowym dla m. st. Warszawy, XIII Wydział Gospodarczy Krajowego Rejestru Sądowego, KRS0000032278, NIP 113-00-20-467, o kapitale zakładowym 39 751 500,00 złotych © Johnson & Johnson Poland Sp. z o.o. 2019; blink/2019/10/9468

[/vc_column_text][/vc_column][/vc_row]